3 ms·
It sounds like the idea is to spend less money on research by seeking to make equivalents (but not generics? and not infringing patents) and then sell them for
by toast0 7y ago
It sounds like the idea is to spend less money on research by seeking to make equivalents (but not generics? and not infringing patents) and then sell them for less. And, presumably, encourage pharmacies to fill with theirs instead of the original.
If the development costs really are lower, and the targeted drugs have enough of a market, it seems totally reasonable to reduce end user costs and still make a bunch of money.
- s1artibartfast 7y agoI'm still skeptical. It seems like this approach would be harder than making a biosimilar drug, which still takes >$100 million and 5-8 years. Pharmacies are not allowed to fill will biologic generics without FDA bio-interchangeable approval, which no biologic in the US has obtained. They would not be able to substitute an alternative drug either.